Secondary prevention following myocardial infarction: Evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues

Quality and Safety in Health Care

Volumn 11, Issue 3, 2002, Pages 230-232

  Underwood, P ^a   Beck, P ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEVINOLIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DIET THERAPY; FEMALE; HEALTH CARE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; NATIONAL HEALTH SERVICE; PATIENT CARE; RETROSPECTIVE STUDY;

EID: 0036752237     PISSN: 09638172     EISSN: None     Source Type: Journal    
DOI: 10.1136/qhc.11.3.230     Document Type: Article

References (20)

1. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
3. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
4. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318:1730-7.
5. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among hiqh-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
6. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE extension (AIREX) study. Acute infarction ramipril efficacy. Lancet 1997;349:1493-7.
7. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
8. Pederson TR, Kiekshus J, Berg K, et al. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-5.
9. EUROASPIRE Study Group. A European society of cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569-82.
10. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events). Heart 1996;75:334-42.
11. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice. BMJ 1998;316:1430-4.
12. Mehta R, Eagle K. Secondary prevention in acute myocardial infarction. BMJ 1998;316:838-42.
13. Cannon CE, Smith Jr SC. Current therapies for secondary prevention after myocardial infarction. Curr Opin Cardiol 1999;14:155-60.
14. Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth. Cardiovasc Drugs Ther 1999;13:435-9.
15. Mason J, Young P, Freemantle N, et al. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: Analysis of individual patient data from studies of left ventricular dysfunction. BMJ 2000;321:1113-6.
16. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
17. Owen OG. Why breakthroughs in research have not been put into practice. Hospital Doctor 1999; 9 December: 30-1.
18. Campbell NC, Ritchie LD, Thain J, et al. Secondary prevention in coronary heart disease: A randomised trial of nurse led clinics in primary care. Heart 1998;80:447-52.
19. Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and ongina: Final results of the Southampton heart integrated care project (SHIP). BMJ 1999;318:706-11.
20. Wiles R, Kinmonth A. Patients' understandings of heart attack: Implications for prevention of recurrence. Patient Educ Couns 2001;44:161-9.